Genexine (XKRX:095700) Stock Based Compensation : ₩2,702 Mil (TTM As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Genexine Stock Based Compensation?

Genexine's Stock Based Compensation for the three months ended in Mar. 2024 was ₩621 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 was ₩2,702 Mil.

Genexine Stock Based Compensation Historical Data

The historical data trend for Genexine's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genexine Stock Based Compensation Chart

Genexine Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

Get a 7-Day Free Trial

3,667.69

3,505.42

2,899.48

3,200.68

2,958.50

Genexine Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Stock Based Compensation	Get a 7-Day Free Trial															877.43	870.92	651.68	558.47	621.42

Genexine Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,702 Mil.

Genexine Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Genexine's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genexine (XKRX:095700) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genexine Inc (XKRX:095700) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

700 Daewangpangyo-ro, Gyeonggi-do, Korea Bio Park Building B, Bundang-gu, Seongnam-si, KOR, 13488

Website

http://www.genexine.com

Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.

Genexine (XKRX:095700) Headlines

No Headlines